AZ-AXWAY
5.8.2020 15:43:07 CEST | Business Wire | Press release
Axway (Euronext: AXW.PA) has been named a Leader in The Forrester Wave™: API Management Solutions Q3 2020 , receiving the highest possible score across eight criteria.
Forrester included 15 vendors in this assessment, grouping by Leaders, Strong Performers, Contenders, and Challengers. Axway received the highest score possible in the product vision, and planned enhancements criteria, with Forrester noting “It had among the best articulations of future API management priorities and products plans...”
“Axway can integrate with and support multiple cloud platforms, multiple integration patterns, as well as API management solutions from other vendors. I am proud that what we consider to be Axway’s vision centered around an Open Platform is being recognized in the market,” said Axway CEO Patrick Donovan. “Our strategy helps customers securely and cost-effectively unlock value to create brilliant business outcomes and customer experiences. Our customers use AMPLIFY API Management to lay foundations for transformation and new business opportunities.”
(See the customer case stories of PermataBank and BNP Paribas Personal Finance.)
According to the report: “Axway customers can benefit from its long-standing B2B product line, including EDI, managed file transfer, and trading partner management, as well as strategic API help from its Catalyst team.” The report also states: “...Axway’s solution was strong in API design and proxy creation, attack protection, microservices support, and organizations as API users.”
“In addition, Axway’s service mesh integration and support for non-Axway gateways (e.g., Amazon API Gateway) extend the solution’s reach and address combined API and microservices strategies,” continues the report. “The solution has a strong messaging gateway and SaaS gateway, embeds Stoplight’s rich API design tool, and features integration platform technology.”
Read more about why Axway was named a Leader in The Forrester Wave™: API Management Solutions Q3 2020.
Click here to view the complete report.
¹The Forrester Wave™: API Management Solutions, Q3 2020, Forrester Research, Inc., August 4, 2020
About Axway
Axway gives heritage IT infrastructure new life, helping more than 11,000 customers worldwide build on what they already have to invent their digital journeys, add new business capabilities, and drive growth ambitions. With the future-proof AMPLIFY™ enterprise integration platform – an innovative combination of APIs, MFT, B2B integration, content services, cloud, communities, and digital ecosystems – we guide continuous innovation and enhance the customer experience faster and more securely than ever before. In business for more than 20 years, Axway (Euronext: AXW.PA) employs over 1,800 people in 18 countries. Learn more at www.axway.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200805005641/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom